This review highlights small-molecule TNFR modulators for cancer and autoimmune diseases, suggesting their clinical potential.
Tumor necrosis factor receptors (TNFR-) are emerging as an important class of pharmaceutical targets that have potential value for the treatment of numerous diseases, including cancer, inflammatory diseases, as well as autoimmune diseases. Although a lot of antibody reagents targeting TNFRs have entered clinical investigation, few of them have been approved for clinical use. More importantly, small-molecule TNFR- inhibitors have rarely entered clinical trials. This brief review focuses on the development of small molecular TNFR- modulators that have been reported in recent decades, with the aim of shedding light on the future discovery and application of more potent and promising small-molecule TNFR modulators.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: